P2RY12 and Schnyder corneal dystrophy: While large randomized control trials of P2Y12 antagonists in SCD patients have shown mixed results in terms of preventing vaso-occlusive complications and have not focused on molecular markers of thrombosis or inflammation (44–46), these antagonists have demonstrated an attenuation of inflammatory signaling in smaller human studies, and in preclinical murine models of SCD (47–49).